Kestra Advisory Services’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Kestra Advisory Services’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-82	Closed	-$225K	–	1890
2020 Q3	$225K	Buy	+82	New	+$3.77K	﹤0.01%	1241

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Kestra Advisory Services's ICPT Position: Q4 2020 in Review

Kestra Advisory Services sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 82 shares — an estimated $225K sold.

Kestra Advisory Services first reported a position in ICPT in Q3 2020 and held it in 1 quarter. The position peaked at $225K in Q3 2020. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

Kestra Advisory Services reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
Kestra Advisory Services sold 82 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $225K.
Kestra Advisory Services first reported a position in Intercept Pharmaceuticals, Inc. in Q3 2020 and held it in 1 quarter.
Kestra Advisory Services's Intercept Pharmaceuticals, Inc. position peaked at $225K in Q3 2020.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Kestra Advisory Services's 13F filing for Q4 2020, filed 20 Jan 2021.